Group 1 - The core viewpoint of the article indicates that Mindray Medical's net profit attributable to shareholders for H1 2025 is 5.069 billion yuan, a year-on-year decrease of 32.96%, with Q2 net profit at 2.440 billion yuan, down 44.55% [1] - International business revenue for H1 2025 reached 8.332 billion yuan, showing a year-on-year growth of 5.39%, accounting for 49.76% of total revenue [1] - Domestic business revenue for H1 2025 was 8.411 billion yuan, reflecting a year-on-year decline of 33.37%, primarily due to the impact of last year's bidding decline and high revenue base from the previous year [1] Group 2 - The company has further consolidated its leading market share in the life information and support equipment sector, with a widening gap from competitors [1] - The business progress is in line with the company's expectations, and international business growth is anticipated to accelerate in H2 2025, particularly in the international in vitro diagnostics product line [1] - The company maintains steady performance growth and aims to share development results with investors, sustaining an "overweight" rating [1]